Latest news with #offshore
Bloomberg
41 minutes ago
- Business
- Bloomberg
Yuan's Worst Week in Six Months Casts Spotlight on PBOC Fixing
The yuan is closing in on its biggest weekly drop in over six months as the dollar rebounds, sharpening the focus on the Chinese central bank's policy signals. China's currency has depreciated 0.7% since July 25 in the offshore market to head for its largest weekly decline since end-January. Its onshore peer slid 0.6% during the period, putting it on track for its worst performance since early February.
Yahoo
2 hours ago
- Business
- Yahoo
Kongsberg Maritime and Noble to co-develop marine technologies for offshore drilling
Kongsberg Maritime and Noble Corporation have signed a Development Programme Framework Agreement to co-develop advanced marine technologies for the offshore drilling sector. The partnership aims to concentrate on the collaborative development, testing, and commercialisation of innovative solutions designed to improve operational efficiency, risk assessment, and sustainability in offshore operations. The first pilot project of this collaboration is set to launch later in the year on the drillship Noble Sam Croft. This initiative marks the beginning of a series of joint development programmes between the two companies. It combines Kongsberg Maritime's extensive marine technology portfolio with Noble's operational expertise and modern fleet of 21 floaters. This collaboration is anticipated to expedite innovation cycles and provide user-focused solutions that create new value for offshore operators. Kongsberg Maritime executive vice president global customer support Jouni Raatikainen said: 'This agreement with Noble underscores our commitment to being a trusted energy transition partner. 'By working closely with forward-thinking companies like Noble, we can co-create technologies that not only improve performance and safety but also support the industry's broader sustainability goals. Noble's progressive approach and openness to innovation make them an ideal partner for this ambitious journey.' In a related development, Kongsberg Maritime has partnered with Solstad, Østensjø, DeepOcean, and Remota to explore the feasibility of remote Dynamic Positioning operations. This partnership will see the pilot project commence later this year on the offshore vessel Normand Sentinel. The project will investigate how remote technology could enhance operational flexibility and expand recruitment prospects within the maritime industry. "Kongsberg Maritime and Noble to co-develop marine technologies for offshore drilling" was originally created and published by Ship Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 hours ago
- Business
- Yahoo
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion Therapeutics' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company's ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company's ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company's authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below). The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the 'Resale Registration Statement'). This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Silexion Therapeutics Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company Contact: Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Capital Markets & IR Contact: Arx | Capital Market AdvisorsNorth American Equities Desksilexion@
Yahoo
15 hours ago
- Business
- Yahoo
Energean and INA announce FID for Irena gas field in Croatia
UK-based Energean, in partnership with INA – INDUSTRIJA NAFTE, has announced the final investment decision (FID) to develop the Irena gas field offshore Croatia. The Irena field is part of the Izabela concession, operated by Edina, a joint venture (JV) equally owned by Energean and INA, a Croatian oil and gas company. Its development plan includes a single platform tied-back to existing infrastructure at the Izabela field. Energean holds a 70% working interest in the concession, which is located in shallow waters at a depth of approximately 45m. The field's P50 reserves are estimated at around 30.5 billion cubic feet gross, equivalent to 5.4 million barrels of oil equivalent. Energean Croatia country manager Francesco Federici said: 'We are thrilled to move forward with the development of the Irena gas field. This FID underscores Energean's commitment to advancing natural resource development in Croatia and the wider Adriatic region. 'This is a strategic investment, and we extend our gratitude to our partner, INA, for their fruitful collaboration over the years and look forward to continued success together.' INA operating director of exploration and production Josip Bubnić added: 'The decision to invest in the development of the Irena gas field is another important step in advancing our strategy of strengthening domestic oil and gas production and ensuring Croatia's long-term energy security. 'We are investing with a clear vision – to enhance energy supply security and maintain our leadership position in the region.' The total estimated capital expenditure for the Irena project stands at €71m ($81.2m), with Energean's share amounting to €50m (£43.23m), reflecting its 70% working interest. Energean's net entitlement gas will be sold under its long-term gas sales agreement with INA. The Irena gas field is expected to commence production in the first half of 2027, with peak production forecast at between eight and ten million standard cubic feet per day gross, equivalent to 1,400–1,700 barrels of oil equivalent per day. "Energean and INA announce FID for Irena gas field in Croatia " was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Saipem secures Scarabeo 8 contract extension with Aker BP until 2027
Aker BP has exercised the option to extend a contract with Saipem for the semi-submersible drilling unit Scarabeo 8 until 31 December 2027. The extension is a direct continuation of the previous one-year contract and solidifies the ongoing collaboration between the two companies. The contract was originally awarded by Aker BP to Saipem for a drilling campaign for a three-year period in March 2022. The $325m (€284.88m) contract included the option of two one-year extensions. The Scarabeo 8, a sixth-generation drilling unit owned by Saipem, will continue to perform drilling activities for Aker BP offshore Norway. Designed to withstand challenging offshore conditions, the derrick deep-water unit is equipped with dynamic positioning and advanced mooring systems, adhering to the highest regulatory standards. Saipem's Scarabeo 8 drilling rig was previously employed on various projects with major oil companies across the Norwegian Continental Shelf (NCS), including the Barents Sea. In a press release, Saipem said this contract extension is a testament to the unit's high performance and Saipem's commitment to safety and efficiency. In July 2024, Aker BP and its partners announced a gas discovery in an exploration well, drilled with the Scarabeo 8 rig in the Barents Sea, nearly 300km off Norway's northern coastline. Designated 7324/8-4 (Hassel), the discovery followed the initial exploration effort at well 7324/6-2 in production licence 1170. Saipem provides engineering services for the design, construction and operation of complex energy infrastructure and plants, both offshore and onshore. With an employee base of 30,000, the company operates in 50 countries through six business lines: Asset Based Services, Drilling, Energy Carriers, Offshore Wind, Robotics & Industrialized Solutions, and Sustainable Infrastructures. "Saipem secures Scarabeo 8 contract extension with Aker BP until 2027" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
